author-photo

Iris Kuss

Bayer HealthCare Pharmaceuticals

32

Papers

1084

Citations

Citation Trend

Filter By

Papers (21) Sort By

Journal Conference Others

222P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) >6 months

2020
Show All
- Source
- Cite
- Save
Citations (1)
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.

2020 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (65)
LBA-09 DAROLUTAMIDE DELAYS PROSTATE-SPECIFIC ANTIGEN PROGRESSION AND TIME TO NEXT ANTICANCER THERAPIES IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER

2019 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (0)
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (30)
ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
PF1-091ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial

2015 International Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (16)